Stock Ratings / Health Care / BNTC / earnings

IRD (23) VOGX (45) ENTA (20) PRLD (41) ⌘ Pro Terminal →

Benitec Biopharma Inc. (BNTC) Next Earnings Date & Expected ±12.5% Move

$8.74 -1.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.71

Benitec Biopharma Inc. (BNTC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $308.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BNTC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BNTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Benitec Biopharma Inc. (NASDAQ: BNTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $8.74 (-1.02% 1D, market cap $308.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BNTC ranks #848 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BNTC compare to IRD and VOGX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BNTC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRD (Opus Genetics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $303.7M) and VOGX (Vogenx Inc) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $295.9M). Among the 5-stock peer group, BNTC leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BNTC?

▼

Per BNTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001808898), Benitec Biopharma Inc. generated $0 in revenue, -$37.9M in net income, and -$23.6M in free cash flow against $190.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.71 (-0.37%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BNTC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY BNTC SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$9.07-7.8% Next Q

Q2 (-2Q)

Grade E$8.36+2.8% Next Q

Q3 (-1Q)

Grade E$8.59+1.7% Next Q

Current

Grade E$8.74-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BNTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BNTC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.30) and Max Pain ($9.18) forces dealer call-delta covering toward $17.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BNTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BNTC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 28, 2026 (~55 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.09 Expected Swing

MODEL EARNINGS SETUP GAUGE

BNTC Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (30/100)Model Risk Weight (70/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-06-30	$0	-$37.9M	-$23.6M	52%
FY 2024	2024-06-30	$0	-$21.8M	-$19.6M	52%
FY 2023	2023-06-30	$0	-$19.6M	-$18.0M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BNTC)

✓Walkthrough of BNTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BNTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.24%▼ DESCENDING CHANNEL

2026-11-02O $8.80H $8.83L $8.74C $8.74VOL 162.5K

RES: $13.54SUP: $7.49SMA50: $10.30SMA200: $11.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BNTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BNTC Butterfly Map → + Track BNTC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BNTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BNTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BNTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BNTC)

Health Care Rank #848 of 1016 ⚔️ IRD vs BNTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BNTC vs. IRD, VOGX, ENTA, PRLD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Benitec Biopharma Inc. (BNTC) ranks #848 by composite RQD confidence (30/100, grade E) and #516 by equity capitalization ($308.1M). Within this direct 5-issuer industry benchmark cohort, BNTC leads on earnings valuation at N/A trailing P/E, while BNTC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with BNTC at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BNTC ACTIVE Benitec Biopharma Inc.	E	30/100	—	—	-35.0%	-1.02%	$308.1M	Benchmark Subject
IRD Opus Genetics Inc.	E	23/100	—	—	-35.0%	+0.55%	$303.7M	/ird-vs-bntc →
VOGX Vogenx Inc	D	45/100	—	—	—	+1.66%	$295.9M	/vogx-vs-bntc →
ENTA Enanta Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-3.95%	$324.7M	/enta-vs-bntc →
PRLD Prelude Therapeutics Incorporated	D-	41/100	—	—	-35.0%	-5.37%	$327.2M	/prld-vs-bntc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001808898

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Benitec Biopharma Inc. (BNTC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$37.9M, operating cash flow of -$23.6M, and free cash flow of -$23.6M (-20.5% YoY). On the balance sheet, BNTC closed FY2025 with $190.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$37.9M	-$23.6M	-$23.6M	$190.7M	—
FY2024 (FY)	2024-06-30	$0	-$21.8M	-$19.4M	-$19.6M	$79.1M	—
FY2023 (FY)	2023-06-30	$0	-$19.6M	-$18.0M	-$18.0M	—	—

3. BNTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BNTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BNTC compare to IRD and VOGX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BNTC?

Where is BNTC trading relative to its 50-day, 200-day, and 52-week technical levels?

BNTC last traded at $8.74 (-1.02% on volume of 135,494 shares), positioning the stock -15.15% below its 50-day simple moving average ($10.30) and -24.13% below its 200-day simple moving average ($11.52). Across its 52-week range of $7.89 to $16.68, BNTC sits at the 9.7% percentile with a 14-day RSI of 44.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.65 to $9.83).

BNTC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is BNTC's next earnings date?

Based on SEC filing cadence, Benitec Biopharma Inc. (BNTC)'s next quarterly reporting window is estimated around Dec 28, 2026.

How much is BNTC stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for BNTC, spanning a range between $7.65 and $9.83.

Direct Sub-Reports: BNTC RQD Cockpit BNTC 12M Forecast BNTC Earnings & Move BNTC Dividends & DRIP BNTC Insiders & 13F BNTC Whale Options BNTC Profit Sankey BNTC News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BNTC — Benitec Biopharma Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:57Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Benitec Biopharma Inc. (BNTC) carries a composite score of 30/100 (E — Roarable Strong Sell — Forensic Risk / Avoid) at a current price of $8.74 (-1.02%). Fundamental cash generation scores 8/20 (ROIC -35.0%, FCF yield -7.66%), institutional 13F whale accumulation scores 3/20, insider conviction scores 3/20, macro regime alignment scores 6/20 (Beta 1.00), and forensic balance-sheet protection scores 10/20 (Altman Z-Score N/A, Piotroski F-Score 2/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (—) and free cash flow conversion relative to the 52-week range of $7.89 – $16.68.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BNTC is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

BNTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Benitec Biopharma Inc. (BNTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BNTC Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 5d ago

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across both d

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 5d ago

Benitec Biopharma Announces Its Interim Data From BB-301 Phase 1b/2a Trial Shows Continued Durable Enhancements In Participants Treated With Low Dose Of BB-301; 100% Response Rate Seen Across All Patients Treated

Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 10d ago

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 10d ago

Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14

Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 28d ago

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

The BB-301 pivotal trial remains on track to begin in mid-2027Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 38d ago

After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)

Benitec Biopharma (BNTC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 188d ago

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patie

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 172d ago

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatm

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BNTC Bull vs. Bear Conversation Board — What's Your Call at $8.74?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BNTC 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $7.77 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BNTC (E • RQD 30/100) a Buy at $8.83?

Welcome to the BNTC (Benitec Biopharma Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.24 (-18.0%)

Spot @ $8.83

Pump the brakes on BNTC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BNTC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Benitec Biopharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $11.13 (+26.0%)

Spot @ $8.83

BNTC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BNTC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.83 (52-wk range $7.89 - $16.68), any beat on forward guidance forces shorts and underweight funds to chase.